Cullinan Therapeutics, Inc.
CGEM
Jodie situation report
Cullinan Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 6 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- CGEM's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if CGEM's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind CGEM
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
AVBPArriVent BioPharma, Inc.competitorMay 11, 2026 ▾
“We believe that our current and future competition for resources and eventually for customers comes from companies that are commercializing or developing candidates targeting EGFRm-positive NSCLC, including, but not limited to, 23 Table of Contents AstraZenec…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CGEM is currently a Early Follower in the organic co-movement group Biotech and Engineering. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CGEM; it is not active in the latest market snapshot.